Brokers Offer Predictions for Kura Oncology’s FY2022 Earnings (KURA)

Kura Oncology (NASDAQ:KURA) – Analysts at Oppenheimer decreased their FY2022 earnings per share (EPS) estimates for Kura Oncology in a research report issued on Monday, March 12th, according to Zacks Investment Research. Oppenheimer analyst L. Cann now anticipates that the company will post earnings per share of $15.22 for the year, down from their prior estimate of $15.89. Oppenheimer currently has a “Buy” rating and a $18.00 target price on the stock.

How to Become a New Pot Stock Millionaire

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Monday, March 12th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.01).

Other analysts also recently issued research reports about the stock. Cann reiterated a “buy” rating and issued a $17.50 price target on shares of Kura Oncology in a research report on Monday, December 11th. BidaskClub upgraded shares of Kura Oncology from a “hold” rating to a “buy” rating in a research report on Wednesday, January 24th. Wedbush started coverage on shares of Kura Oncology in a research report on Tuesday, December 26th. They issued a “buy” rating and a $19.00 price target for the company. Zacks Investment Research upgraded shares of Kura Oncology from a “hold” rating to a “buy” rating and set a $22.00 price target for the company in a research report on Wednesday, March 21st. Finally, Citigroup set a $28.00 price target on shares of Kura Oncology and gave the company a “buy” rating in a research report on Friday, February 16th. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $22.00.

KURA stock opened at $16.70 on Wednesday. Kura Oncology has a 12 month low of $5.90 and a 12 month high of $24.02. The firm has a market capitalization of $612.04, a P/E ratio of -10.99 and a beta of 4.21. The company has a quick ratio of 9.44, a current ratio of 9.44 and a debt-to-equity ratio of 0.07.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. increased its stake in Kura Oncology by 49.1% in the 4th quarter. BlackRock Inc. now owns 1,524,817 shares of the company’s stock valued at $23,331,000 after buying an additional 502,296 shares during the period. Nexthera Capital LP increased its stake in Kura Oncology by 72.3% in the 4th quarter. Nexthera Capital LP now owns 445,550 shares of the company’s stock valued at $6,817,000 after buying an additional 187,034 shares during the period. Vanguard Group Inc. increased its stake in Kura Oncology by 13.0% in the 2nd quarter. Vanguard Group Inc. now owns 433,868 shares of the company’s stock valued at $4,035,000 after buying an additional 50,033 shares during the period. Millennium Management LLC increased its stake in Kura Oncology by 35.7% in the 4th quarter. Millennium Management LLC now owns 303,905 shares of the company’s stock valued at $4,650,000 after buying an additional 79,989 shares during the period. Finally, EAM Investors LLC acquired a new position in Kura Oncology in the 3rd quarter valued at $2,884,000. 58.56% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/04/07/oppenheimer-equities-analysts-lower-earnings-estimates-for-kura-oncology-inc-kura.html.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

Get a free copy of the Zacks research report on Kura Oncology (KURA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply